Scholar Rock retira la planta de Novo Nordisk de la solicitud de comercialización de un medicamento para la debilidad muscular

Scholar Rock Removes Novo Nordisk Indiana Facility from FDA Application for Rare Muscle Weakness Drug

Scholar Rock announced it will remove Novo Nordisk's (formerly Catalent's) Indiana manufacturing facility from its FDA biologics license application for a treatment targeting a rare neuromuscular disease. The regulatory filing adjustment comes as the company seeks approval for its muscle weakness therapy.